Cargando…

Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance

BACKGROUND: Background incidence rates are critical in pharmacovigilance to facilitate identification of vaccine safety signals. We estimated background incidence rates of 11 adverse events of special interest related to COVID-19 vaccines in Ontario, Canada. METHODS: We conducted a population-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasreen, Sharifa, Calzavara, Andrew, Buchan, Sarah A., Thampi, Nisha, Johnson, Caitlin, Wilson, Sarah E., Kwong, Jeffrey C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042732/
https://www.ncbi.nlm.nih.gov/pubmed/35527057
http://dx.doi.org/10.1016/j.vaccine.2022.04.065
_version_ 1784694725261918208
author Nasreen, Sharifa
Calzavara, Andrew
Buchan, Sarah A.
Thampi, Nisha
Johnson, Caitlin
Wilson, Sarah E.
Kwong, Jeffrey C.
author_facet Nasreen, Sharifa
Calzavara, Andrew
Buchan, Sarah A.
Thampi, Nisha
Johnson, Caitlin
Wilson, Sarah E.
Kwong, Jeffrey C.
author_sort Nasreen, Sharifa
collection PubMed
description BACKGROUND: Background incidence rates are critical in pharmacovigilance to facilitate identification of vaccine safety signals. We estimated background incidence rates of 11 adverse events of special interest related to COVID-19 vaccines in Ontario, Canada. METHODS: We conducted a population-based retrospective observational study using linked health administrative databases for hospitalizations and emergency department visits among Ontario residents. We estimated incidence rates of Bell’s palsy, idiopathic thrombocytopenia, febrile convulsions, acute disseminated encephalomyelitis, myocarditis, pericarditis, Kawasaki disease, Guillain-Barré syndrome, transverse myelitis, acute myocardial infarction, and anaphylaxis during five pre-pandemic years (2015–2019) and 2020. RESULTS: The average annual population was 14 million across all age groups with 51% female. The pre-pandemic mean annual rates per 100,000 population during 2015–2019 were 191 for acute myocardial infarction, 43.9 for idiopathic thrombocytopenia, 28.8 for anaphylaxis, 27.8 for Bell’s palsy, 25.0 for febrile convulsions, 22.8 for acute disseminated encephalomyelitis, 11.3 for myocarditis/pericarditis, 8.7 for pericarditis, 2.9 for myocarditis, 2.0 for Kawasaki disease, 1.9 for Guillain-Barré syndrome, and 1.7 for transverse myelitis. Females had higher rates of acute disseminated encephalomyelitis, transverse myelitis and anaphylaxis while males had higher rates of myocarditis, pericarditis, and Guillain-Barré syndrome. Bell’s palsy, acute disseminated encephalomyelitis, and Guillain-Barré syndrome increased with age. The mean rates of myocarditis and/or pericarditis increased with age up to 79 years; males had higher rates than females: from 12 to 59 years for myocarditis and ≥12 years for pericarditis. Febrile convulsions and Kawasaki disease were predominantly childhood diseases and generally decreased with age. CONCLUSIONS: Our estimated background rates will permit estimating numbers of expected events for these conditions and facilitate detection of potential safety signals following COVID-19 vaccination.
format Online
Article
Text
id pubmed-9042732
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-90427322022-04-27 Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance Nasreen, Sharifa Calzavara, Andrew Buchan, Sarah A. Thampi, Nisha Johnson, Caitlin Wilson, Sarah E. Kwong, Jeffrey C. Vaccine Article BACKGROUND: Background incidence rates are critical in pharmacovigilance to facilitate identification of vaccine safety signals. We estimated background incidence rates of 11 adverse events of special interest related to COVID-19 vaccines in Ontario, Canada. METHODS: We conducted a population-based retrospective observational study using linked health administrative databases for hospitalizations and emergency department visits among Ontario residents. We estimated incidence rates of Bell’s palsy, idiopathic thrombocytopenia, febrile convulsions, acute disseminated encephalomyelitis, myocarditis, pericarditis, Kawasaki disease, Guillain-Barré syndrome, transverse myelitis, acute myocardial infarction, and anaphylaxis during five pre-pandemic years (2015–2019) and 2020. RESULTS: The average annual population was 14 million across all age groups with 51% female. The pre-pandemic mean annual rates per 100,000 population during 2015–2019 were 191 for acute myocardial infarction, 43.9 for idiopathic thrombocytopenia, 28.8 for anaphylaxis, 27.8 for Bell’s palsy, 25.0 for febrile convulsions, 22.8 for acute disseminated encephalomyelitis, 11.3 for myocarditis/pericarditis, 8.7 for pericarditis, 2.9 for myocarditis, 2.0 for Kawasaki disease, 1.9 for Guillain-Barré syndrome, and 1.7 for transverse myelitis. Females had higher rates of acute disseminated encephalomyelitis, transverse myelitis and anaphylaxis while males had higher rates of myocarditis, pericarditis, and Guillain-Barré syndrome. Bell’s palsy, acute disseminated encephalomyelitis, and Guillain-Barré syndrome increased with age. The mean rates of myocarditis and/or pericarditis increased with age up to 79 years; males had higher rates than females: from 12 to 59 years for myocarditis and ≥12 years for pericarditis. Febrile convulsions and Kawasaki disease were predominantly childhood diseases and generally decreased with age. CONCLUSIONS: Our estimated background rates will permit estimating numbers of expected events for these conditions and facilitate detection of potential safety signals following COVID-19 vaccination. Published by Elsevier Ltd. 2022-05-26 2022-04-27 /pmc/articles/PMC9042732/ /pubmed/35527057 http://dx.doi.org/10.1016/j.vaccine.2022.04.065 Text en Crown Copyright © 2022 Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Nasreen, Sharifa
Calzavara, Andrew
Buchan, Sarah A.
Thampi, Nisha
Johnson, Caitlin
Wilson, Sarah E.
Kwong, Jeffrey C.
Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
title Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
title_full Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
title_fullStr Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
title_full_unstemmed Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
title_short Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
title_sort background incidence rates of adverse events of special interest related to covid-19 vaccines in ontario, canada, 2015 to 2020, to inform covid-19 vaccine safety surveillance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042732/
https://www.ncbi.nlm.nih.gov/pubmed/35527057
http://dx.doi.org/10.1016/j.vaccine.2022.04.065
work_keys_str_mv AT nasreensharifa backgroundincidenceratesofadverseeventsofspecialinterestrelatedtocovid19vaccinesinontariocanada2015to2020toinformcovid19vaccinesafetysurveillance
AT calzavaraandrew backgroundincidenceratesofadverseeventsofspecialinterestrelatedtocovid19vaccinesinontariocanada2015to2020toinformcovid19vaccinesafetysurveillance
AT buchansaraha backgroundincidenceratesofadverseeventsofspecialinterestrelatedtocovid19vaccinesinontariocanada2015to2020toinformcovid19vaccinesafetysurveillance
AT thampinisha backgroundincidenceratesofadverseeventsofspecialinterestrelatedtocovid19vaccinesinontariocanada2015to2020toinformcovid19vaccinesafetysurveillance
AT johnsoncaitlin backgroundincidenceratesofadverseeventsofspecialinterestrelatedtocovid19vaccinesinontariocanada2015to2020toinformcovid19vaccinesafetysurveillance
AT wilsonsarahe backgroundincidenceratesofadverseeventsofspecialinterestrelatedtocovid19vaccinesinontariocanada2015to2020toinformcovid19vaccinesafetysurveillance
AT kwongjeffreyc backgroundincidenceratesofadverseeventsofspecialinterestrelatedtocovid19vaccinesinontariocanada2015to2020toinformcovid19vaccinesafetysurveillance
AT backgroundincidenceratesofadverseeventsofspecialinterestrelatedtocovid19vaccinesinontariocanada2015to2020toinformcovid19vaccinesafetysurveillance